# Multitude Therapeutics

Source: https://onco.cc/companies/multitude-therapeutics/  
OnCo record `multitude-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Multitude Therapeutics is a China-based biotechnology company running 4 late-stage cancer trials of AMT-116, AMT-676 and AMT-253 in colorectal cancer, melanoma and non-small-cell lung cancer.

## Summary

Multitude Therapeutics, based in Shanghai, China, is a biotechnology company. Multitude Therapeutics is a clinical-stage biotechnology company in China developing antibody-drug conjugate therapies for cancer, using its PAD molecular design platform and MabArray target discovery platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AMT-116, AMT-676, AMT-253 and AK112 in colorectal cancer, melanoma and non-small-cell lung cancer. The largest, NCT07474727 (A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Multitude Therapeutics Inc.
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.multitudetherapeutics.com

## Sources

- Official website: https://www.multitudetherapeutics.com
- ClinicalTrials.gov: trials led by Multitude Therapeutics: https://clinicaltrials.gov/search?lead=Multitude%20Therapeutics%20Inc.

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- trials: [A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer](https://onco.cc/trials/nct07474727/), [AMT-116 in Combination With AK112 in Patients With Lung Cancer](https://onco.cc/trials/nct07590531/), [AMT-116 in Patients with Solid Tumors](https://onco.cc/trials/nct06782334/), [AMT-253 in Patients With Advanced Solid Tumours](https://onco.cc/trials/nct06209580/), [Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can](https://onco.cc/trials/nct07718737/)
- drugs: [AMT-116](https://onco.cc/drugs/amt-116/)

---
JSON: https://onco.cc/api/v1/entities/multitude-therapeutics.json